aSection of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06511, USA bDepartment of Pathology, Yale School of Medicine, New Haven, CT 06511, USA cDepartment ...

WASHINGTON — MRI-guided stereotactic body radiotherapy (SBRT) showed sustained benefits over CT-guided SBRT for prostate cancer, in a study. Amar Kishan, MD, of UCLA Health, presented the 2-year ...

Baseline MRI PI-RADS score suggests prognosis and may improve upfront risk stratification and eligibility for prostate cancer active surveillance. Higher baseline MRI PI-RADS score is associated ...

After a median follow-up of 3.9 years, the researchers found that prostate cancer was detected in 185 of the 6,575 men (2.8 percent) in the MRI-targeted biopsy group and in 298 of the 6,578 men (4 ...

As the main type of renal cell carcinoma (RCC), clear cell RCC (ccRCC) is often associated with the deletion or mutation of the von Hippel Lindau (VHL) gene, enhancement of glucose and lipid ...

Seven weeks later, magnetic resonance imaging (MRI ... contrast material, reportedly showed the enhancing 24-mm mass in the upper pole of the left kidney that was suggestive of renal-cell carcinoma.

Data on the efficacy and safety of screening for prostate cancer with magnetic resonance imaging (MRI) are needed from studies of follow-up screening. In a population-based trial that started in ...

Background: Sarcomatoid urothelial carcinoma (SUC) is a rare renal malignancy. Its biological malignancy is high, the prognosis is poor, diagnostic and treatment options are few, and there is no ...

It’s important for patients with renal clear cell (RCC) carcinoma — a common type of kidney cancer — to consider the challenges associated with receiving Fotivda (tivozanib). Fotivda is a vascular ...

For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, including one immune checkpoint inhibitor (ICI), tivozanib has efficacy ...

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma. NKT2152, a novel oral HIF2α inhibitor, demonstrated promising objective ...